Read by QxMD icon Read

Breast Cancer Research: BCR

Kimberly D van der Willik, Vincent Koppelmans, Michael Hauptmann, Annette Compter, M Arfan Ikram, Sanne B Schagen
BACKGROUND: Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related cognitive impairment. We investigated levels of blood cell-based inflammatory markers in breast cancer survivors on average 20 years after chemotherapy and explored the relation between these markers and global cognitive performance. METHODS: One hundred sixty-six breast cancer survivors who received post-surgical radiotherapy and six cycles of adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy on average 20 years before enrollment were compared with 1344 cancer-free women from a population-based sample (50-80 years old)...
November 15, 2018: Breast Cancer Research: BCR
Cody Ramin, Betty J May, Richard B S Roden, Mikiaila M Orellana, Brenna C Hogan, Michelle S McCullough, Dana Petry, Deborah K Armstrong, Kala Visvanathan
BACKGROUND: Osteoporosis, an indicator of significant bone loss, has been consistently reported among older breast cancer survivors. Data are limited on the incidence of osteopenia, an earlier indicator of bone loss, and osteoporosis in younger breast cancer survivors compared with cancer-free women. METHODS: We prospectively examined bone loss in 211 breast cancer survivors (mean age at breast cancer diagnosis = 47 years) compared with 567 cancer-free women in the same cohort with familial risk for breast cancer...
November 13, 2018: Breast Cancer Research: BCR
Jaroslaw Suchanski, Jedrzej Grzegrzolka, Tomasz Owczarek, Pawel Pasikowski, Aleksandra Piotrowska, Bartlomiej Kocbach, Aleksandra Nowak, Piotr Dziegiel, Andrzej Wojnar, Maciej Ugorski
BACKGROUND: We have previously shown that galactosylceramide (GalCer) affects the tumourigenic and metastatic properties of breast cancer cells by acting as an anti-apoptotic molecule. Since GalCer is a precursor molecule in the synthesis of sulfatides, the present study was aimed to define the role of sulfatides in apoptosis and breast cancer progression. METHODS: Expression of GAL3ST1 in breast cancer cell lines and breast cancer tissue specimens was analysed using real-time PCR, western blotting and immunohistochemistry analysis...
November 6, 2018: Breast Cancer Research: BCR
John L Hopper, Gillian S Dite, Robert J MacInnis, Yuyan Liao, Nur Zeinomar, Julia A Knight, Melissa C Southey, Roger L Milne, Wendy K Chung, Graham G Giles, Jeanine M Genkinger, Sue-Anne McLachlan, Michael L Friedlander, Antonis C Antoniou, Prue C Weideman, Gord Glendon, Stephanie Nesci, Irene L Andrulis, Saundra S Buys, Mary B Daly, Esther M John, Kelly Anne Phillips, Mary Beth Terry
BACKGROUND: The association between body mass index (BMI) and risk of breast cancer depends on time of life, but it is unknown whether this association depends on a woman's familial risk. METHODS: We conducted a prospective study of a cohort enriched for familial risk consisting of 16,035 women from 6701 families in the Breast Cancer Family Registry and the Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer followed for up to 20 years (mean 10...
November 3, 2018: Breast Cancer Research: BCR
(no author information available yet)
No abstract text is available yet for this article.
November 2, 2018: Breast Cancer Research: BCR
Serena P H Mao, Minji Park, Ramon M Cabrera, John R Christin, George S Karagiannis, Maja H Oktay, Dietmar M W Zaiss, Scott I Abrams, Wenjun Guo, John S Condeelis, Paraic A Kenny, Jeffrey E Segall
BACKGROUND: Amphiregulin (AREG), a ligand of the epidermal growth factor receptor, is not only essential for proper mammary ductal development, but also associated with breast cancer proliferation and growth. In the absence of AREG, mammary ductal growth is stunted and fails to expand. Furthermore, suppression of AREG expression in estrogen receptor-positive breast tumor cells inhibits in-vitro and in-vivo growth. METHODS: We crossed AREG-null (AREG-/- ) mice with the murine luminal B breast cancer model, MMTV-PyMT (PyMT), to generate spontaneous breast tumors that lack AREG (AREG-/- PyMT)...
October 26, 2018: Breast Cancer Research: BCR
Brooke N McKnight, Nerissa T Viola-Villegas
BACKGROUND: De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-receptor tyrosine kinase, is identified as a major mechanism of trastuzumab resistance, with its activation stabilizing aberrant HER2 signaling, thus making it an attractive target for inhibition. Here, we explored the causal relationship between Src and HER2 by examining the potential of 89 Zr-trastuzumab as a surrogate imaging marker of Src activity upon inhibition with dasatinib in HER2+ breast cancer...
October 25, 2018: Breast Cancer Research: BCR
Eleanor Broadberry, James McConnell, Jack Williams, Nan Yang, Egor Zindy, Angela Leek, Rachel Waddington, Leena Joseph, Miles Howe, Qing-Jun Meng, Charles H Streuli
BACKGROUND: Circadian rhythms maintain tissue homeostasis during the 24-h day-night cycle. Cell-autonomous circadian clocks play fundamental roles in cell division, DNA damage responses and metabolism. Circadian disruptions have been proposed as a contributing factor for cancer initiation and progression, although definitive evidence for altered molecular circadian clocks in cancer is still lacking. In this study, we looked at circadian clocks in breast cancer. METHODS: We isolated primary tumours and normal tissues from the same individuals who had developed breast cancer with no metastases...
October 22, 2018: Breast Cancer Research: BCR
Xuxiang Liu, Minghui Cao, Melanie Palomares, Xiwei Wu, Arthur Li, Wei Yan, Miranda Y Fong, Wing-Chung Chan, Shizhen Emily Wang
BACKGROUND: Bone is one of the most frequent metastatic sites of advanced breast cancer. Current therapeutic agents aim to inhibit osteoclast-mediated bone resorption but only have palliative effects. During normal bone remodeling, the balance between bone resorption and osteoblast-mediated bone formation is essential for bone homeostasis. One major function of osteoblast during bone formation is to secrete type I procollagen, which will then be processed before being crosslinked and deposited into the bone matrix...
October 22, 2018: Breast Cancer Research: BCR
Sruthi Ravindranathan, Khue G Nguyen, Samantha L Kurtz, Haven N Frazier, Sean G Smith, Bhanu Prasanth Koppolu, Narasimhan Rajaram, David A Zaharoff
BACKGROUND: Although metastasis is ultimately responsible for about 90% of breast cancer mortality, the vast majority of breast-cancer-related deaths are due to progressive recurrences from non-metastatic disease. Current adjuvant therapies are unable to prevent progressive recurrences for a significant fraction of patients with breast cancer. Autologous tumor cell vaccines (ATCVs) are a safe and potentially useful strategy to prevent breast cancer recurrence, in a personalized and patient-specific manner, following standard-of-care tumor resection...
October 22, 2018: Breast Cancer Research: BCR
Safiah Olabi, Ahmet Ucar, Keith Brennan, Charles H Streuli
BACKGROUND: Stem cells are precursors for all mammary epithelia, including ductal and alveolar epithelia, and myoepithelial cells. In vivo mammary epithelia reside in a tissue context and interact with their milieu via receptors such as integrins. Extracellular matrix receptors coordinate important cellular signalling platforms, of which integrins are the central architects. We have previously shown that integrins are required for mammary epithelial development and function, including survival, cell cycle, and polarity, as well as for the expression of mammary-specific genes...
October 22, 2018: Breast Cancer Research: BCR
Gabriel N Hortobagyi
Endocrine therapy is recommended for patients with hormone receptor-positive (HR+ ) advanced and metastatic breast cancer without visceral crisis (symptomatic visceral disease). However, many patients experience disease progression during treatment, and most patients eventually develop endocrine resistance. Therefore, it is important to identify treatment options that prolong the effectiveness of first-line endocrine therapies. Ribociclib is an orally bioavailable cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved for use in combination with an aromatase inhibitor for the treatment of HR+ , human epidermal growth factor receptor 2-negative (HER2- ) advanced breast cancer...
October 19, 2018: Breast Cancer Research: BCR
Christina M Dieli-Conwright, Kerry S Courneya, Wendy Demark-Wahnefried, Nathalie Sami, Kyuwan Lee, Frank C Sweeney, Christina Stewart, Thomas A Buchanan, Darcy Spicer, Debu Tripathy, Leslie Bernstein, Joanne E Mortimer
BACKGROUND: Exercise is an effective strategy to improve quality of life and physical fitness in breast cancer survivors; however, few studies have focused on the early survivorship period, minorities, physically inactive and obese women, or tested a combined exercise program and measured bone health. Here, we report the effects of a 16-week aerobic and resistance exercise intervention on patient-reported outcomes, physical fitness, and bone health in ethnically diverse, physically inactive, overweight or obese breast cancer survivors...
October 19, 2018: Breast Cancer Research: BCR
Elin Borgen, Maria C Rypdal, Maria Soledad Sosa, Anne Renolen, Ellen Schlichting, Per E Lønning, Marit Synnestvedt, Julio A Aguirre-Ghiso, Bjørn Naume
BACKGROUND: The presence of disseminated tumor cells (DTCs) in bone marrow (BM) is an independent prognostic factor in early breast cancer but does not uniformly predict outcome. Tumor cells can persist in a quiescent state over time, but clinical studies of markers predicting the awakening potential of DTCs are lacking. Recently, experiments have shown that NR2F1 (COUP-TF1) plays a key role in dormancy signaling. METHODS: We analyzed the NR2F1 expression in DTCs by double immunofluorescence (DIF) staining of extra cytospins prepared from 114 BM samples from 86 selected DTC-positive breast cancer patients...
October 16, 2018: Breast Cancer Research: BCR
Neethan Amit Lobo, Maider Zabala, Dalong Qian, Michael F Clarke
BACKGROUND: Recent studies in murine mammary tissue have identified functionally distinct cell populations that may be isolated by surface phenotype or lineage tracing. Previous groups have shown that CD24med CD49fhigh cells enriched for long-lived mammary epithelial cells can be serially transplanted. METHODS: Flow cytometry-based enrichment of distinct phenotypic populations was assessed for their gene expression profiles and functional proliferative attributes in vitro and in vivo...
October 10, 2018: Breast Cancer Research: BCR
John A Reid, Peter M Mollica, Robert D Bruno, Patrick C Sachs
BACKGROUND: Standard three-dimensional (3D) in vitro culture techniques, such as those used for mammary epithelial cells, rely on random distribution of cells within hydrogels. Although these systems offer advantages over traditional 2D models, limitations persist owing to the lack of control over cellular placement within the hydrogel. This results in experimental inconsistencies and random organoid morphology. Robust, high-throughput experimentation requires greater standardization of 3D epithelial culture techniques...
October 10, 2018: Breast Cancer Research: BCR
Zorana Jovanovic Andersen, Jeanette Therming Jørgensen, Lea Elsborg, Søren Nymand Lophaven, Claus Backalarz, Jens Elgaard Laursen, Torben Holm Pedersen, Mette Kildevæld Simonsen, Elvira Vaclavik Bräuner, Elsebeth Lynge
BACKGROUND: Exposure to road traffic noise was associated with increased risk of estrogen receptor (ER)-negative (ER-) breast cancer in a previous cohort study, but not with overall or ER-positive (ER+) breast cancer, or breast cancer prognosis. We examined the association between long-term exposure to road traffic noise and incidence of breast cancer, overall and by ER and progesterone receptor (PR) status. METHODS: We used the data from a nationwide Danish Nurse Cohort on 22,466 female nurses (age > 44 years) who at recruitment in 1993 or 1999 reported information on breast cancer risk factors...
October 5, 2018: Breast Cancer Research: BCR
Anthony J Swerdlow, Lauren B Wright, Minouk J Schoemaker, Michael E Jones
BACKGROUND: Parity and age at first pregnancy are well-established risk factors for breast cancer, but the effects of other characteristics of pregnancies are uncertain and the literature is inconsistent. METHODS: In a cohort of 83,451 parous women from the general population of the UK, which collected detailed information on each pregnancy and a wide range of potential confounders, we investigated the associations of length of gestation and birthweight of offspring in a woman's pregnancies with her breast cancer risk, adjusting for a full range of non-reproductive as well as reproductive risk factors unlike in previous large studies...
October 5, 2018: Breast Cancer Research: BCR
Nathan A Ungerleider, Sonia G Rao, Ashkan Shahbandi, Douglas Yee, Tianhua Niu, Wesley D Frey, James G Jackson
BACKGROUND: Previous studies on the role of TP53 mutation in breast cancer treatment response and survival are contradictory and inconclusive, limited by the use of different endpoints to determine clinical significance and by small sample sizes that prohibit stratification by treatment. METHODS: We utilized large datasets to examine overall survival according to TP53 mutation status in patients across multiple clinical features and treatments. RESULTS: Confirming other studies, we found that in all patients and in hormone therapy-treated patients, TP53 wild-type status conferred superior 5-year overall survival, but survival curves crossed at 10 or more years...
October 1, 2018: Breast Cancer Research: BCR
Hui Zhang, Tricia Fredericks, Gaofeng Xiong, Yifei Qi, Piotr G Rychahou, Jia-Da Li, Taina Pihlajaniemi, Wei Xu, Ren Xu
BACKGROUND: Increased collagen expression and deposition are associated with cancer progression and poor prognosis in breast cancer patients. However, function and regulation of membrane-associated collagen in breast cancer have not been determined. Collagen XIII is a type II transmembrane protein within the collagen superfamily. Experiments in tissue culture and knockout mouse models show that collagen XIII is involved in cell adhesion and differentiation of certain cell types. In the present study, we determined roles of collagen XIII in breast cancer progression and metastasis...
October 1, 2018: Breast Cancer Research: BCR
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"